AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26268815 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 24752228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic resistance exercise (HRE) - 1 repetition maximum (1 RM) control contractions and three sets of 13 RM (SET1-3)
Number of subjects: 11
Study 24312382 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-caloric sweetened (NS) drink
Number of subjects: 40
Study 24312382 — intervention group
Group type: COMPARATOR
Intervention: Sugar sweetened (SS) drink
Number of subjects: 40
Study 24312382 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt drink
Number of subjects: 40
Study 24312382 — intervention group
Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 40
Study 19808841 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-based skills training program for dementia caregiving dyads; specific details on dosage and duration not available.
Number of subjects: 0
Study 19808841 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control group not available.
Number of subjects: 0
Study 18438203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS)
Number of subjects: 1200
Study 18438203 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MT)
Number of subjects: 1200
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (HAL) at 1.0 MAC
Number of subjects: 35
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) at 1.0 MAC
Number of subjects: 35
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV) at 1.0 MAC
Number of subjects: 35
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (HAL) at 0.5 MAC
Number of subjects: 35
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO) at 0.5 MAC
Number of subjects: 35
Study 16628063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV) at 0.5 MAC
Number of subjects: 35
Study 12913198 — intervention group
Group type: COMPARATOR
Intervention: SIVD
Number of subjects: 13
Study 11044542 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 57
Study 11044542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate Therapy
Number of subjects: 57
Study 11044542 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated women)
Number of subjects: 57
Study 8863905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily for 7 days)
Number of subjects: 20
Study 8863905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1889980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0
Study 1889980 — intervention group
Group type: COMPARATOR
Intervention: Placebo or other antimigraine drugs
Number of subjects: 0
Study 6647211 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose salbutamol given by domestic nebulizers
Number of subjects: 0
Study 31023422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month (50 h) educational intervention to instill healthy behaviors related to diet, physical activity, body/heart awareness, and emotion management.
Number of subjects: 562
Study 31023422 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (control)
Number of subjects: 562
Study 31023422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month (50 h) educational intervention
Number of subjects: 562
Study 29912906 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 0
Study 27506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine complex supplement (Viviscal® Man); administered twice daily for 180 days
Number of subjects: 0
Study 27506633 — intervention group
Group type: COMPARATOR
Intervention: Placebo; administered twice daily for 180 days
Number of subjects: 0
Study 23824236 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for depression and subsequent care support
Number of subjects: 900
Study 22030715 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 2
Study 22030715 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 2
Study 22030715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 20467310 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga (IY)
Number of subjects: 24
Study 17394695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 493
Study 17394695 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 493
Study 17394695 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed patients (first 3 months follow-up)
Number of subjects: 493
Study 17394695 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed patients (after 3 years)
Number of subjects: 493
Study 17394695 — intervention group
Group type: EXPERIMENTAL
Intervention: Known patients (after 3 years)
Number of subjects: 493
Study 15802371 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry (AR)
Number of subjects: 10
Study 12217456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 12217456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 12217456 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Fluoxetine and CBT)
Number of subjects: 0
Study 10543268 — intervention group
Group type: EXPERIMENTAL
Intervention: High PS (increased by at least 5 cmH2O)
Number of subjects: 8
Study 10543268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PS (decreased by at least 5 cmH2O)
Number of subjects: 8
Study 10543268 — intervention group
Group type: COMPARATOR
Intervention: Baseline PS
Number of subjects: 8
Study 8847943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 8
Study 8847943 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8
Study 8847943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 8
Study 8847943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2159838 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy (cisplatin 100 mg/m2, cyclophosphamide 600 mg/m2, vindesine 3 mg/m2)
Number of subjects: 26
Study 2159838 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 26
Study 453063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (18.0 g crude fiber)
Number of subjects: 7
Study 453063 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet (1.0 g crude fiber)
Number of subjects: 7
Study 30277014 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless transcutaneous neuromodulation (TN)
Number of subjects: 60
Study 30277014 — intervention group
Group type: COMPARATOR
Intervention: Sham-TN
Number of subjects: 60
Study 27578535 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-frequency medium duration (40 Hz × 360 s)
Number of subjects: 80
Study 27578535 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 80
Study 25795954 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (20 Hz and 2 mm, twice a week for 8 months)
Number of subjects: 37
Study 25795954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 37
Study 22718223 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting glucose level of 6.1 mmol/L or more
Number of subjects: 250
Study 22718223 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain-related disability
Number of subjects: 250
Study 22718223 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 250
Study 22718223 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol (EQ)-index
Number of subjects: 250
Study 22718223 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol (EQ)-visual analogue scale
Number of subjects: 250
Study 22115000 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system patch wear times (9, 10, 11, and 12 hours per day)
Number of subjects: 26
Study 19190206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 19190206 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (glucantime)
Number of subjects: 0
Study 17041083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence A: 0.016-inch NiTi, 0.018 x 0.025-inch NiTi, 0.019 x 0.025-inch SS
Number of subjects: 154
Study 17041083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence B: 0.016-inch NiTi, 0.016-inch SS, 0.020-inch SS, 0.019 x 0.025-inch SS
Number of subjects: 154
Study 17041083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence C: 0.016 x 0.022-inch Cu NiTi, 0.019 x 0.025-inch CuNiTi, 0.019 x 0.025-inch SS
Number of subjects: 154
Study 14652119 — intervention group
Group type: COMPARATOR
Intervention: LMA (standard Laryngeal Mask Airway)
Number of subjects: 60
Study 14652119 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMA (LMA-ProSeal)
Number of subjects: 60
Study 10722781 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI)
Number of subjects: 10
Study 10722781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI)
Number of subjects: 10
Study 10722781 — intervention group
Group type: COMPARATOR
Intervention: Noncarbohydrate Control (PL)
Number of subjects: 10
Study 9114686 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 190
Study 9114686 — intervention group
Group type: COMPARATOR
Intervention: Plain catgut sutures
Number of subjects: 190
Study 9114686 — intervention group
Group type: COMPARATOR
Intervention: Skin tapes
Number of subjects: 190
Study 1589701 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 100
Study 1589701 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg) plus amiloride (5 mg)
Number of subjects: 100
Study 3897071 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 0
Study 3897071 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 2 mg twice a day
Number of subjects: 0
Study 3897071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31513671 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload (EOL) exercise
Number of subjects: 10
Study 31513671 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weightlifting (TW) exercise
Number of subjects: 10
Study 29573567 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD therapy
Number of subjects: 24
Study 29573567 — intervention group
Group type: COMPARATOR
Intervention: Standard heart failure therapy (with or without sildenafil, nitrates, or endothelin receptor antagonists)
Number of subjects: 24
Study 26759138 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose aspirin (81 mg/day) plus folic acid (400 mcg/day)
Number of subjects: 1228
Study 26759138 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus folic acid (400 mcg/day)
Number of subjects: 1228
Study 25305054 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact care with four physical 10-minute consultations/year and three non-physical 10-minute consultations/year
Number of subjects: 597
Study 25305054 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 597
Study 22730950 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents (CCP)
Number of subjects: 250
Study 22730950 — intervention group
Group type: COMPARATOR
Intervention: Becoming a Parent Program (BAP)
Number of subjects: 250
Study 19182989 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling and home telemonitoring (Thin-Link(R) home telemonitoring scale and biweekly counseling for 6 months)
Number of subjects: 0
Study 19182989 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start group (no immediate intervention)
Number of subjects: 0
Study 17478360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 106
Study 17478360 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 106
Study 14748874 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous somatostatin infusion for 12 hours starting 30 minutes before ERCP
Number of subjects: 372
Study 14748874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intravenous injection of somatostatin at the time of cannulation
Number of subjects: 372
Study 14748874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 14748874 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin groups (both continuous infusion and bolus)
Number of subjects: 372
Study 12073055 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with the Nijmegen technique (4 fractions of 6 Gy directed to the macular area)
Number of subjects: 63
Study 12073055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study 9642631 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of one obese parent
Number of subjects: 886
Study 9642631 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of two obese parents
Number of subjects: 886
Study 9642631 — intervention group
Group type: COMPARATOR
Intervention: Children of normal weight parents
Number of subjects: 886
Study 9642631 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (obesity onset at mean age of 5.3 +/- 2.6 years)
Number of subjects: 886
Study 9642631 — intervention group
Group type: COMPARATOR
Intervention: Group A (obesity always present)
Number of subjects: 886
Study 7877160 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) positions
Number of subjects: 0
Study 2713259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphencyprone
Number of subjects: 17
Study 2713259 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin gel (Retin A)
Number of subjects: 17
Study 2713259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphencyprone (after 20 weeks of tretinoin)
Number of subjects: 17
Study 1100302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (DP) intravenous administration at dosages ranging from 0.05 to 2.0 mg/kg
Number of subjects: 18
Study 1100302 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/ml parenteral solution of DP
Number of subjects: 18
Study 1100302 — intervention group
Group type: COMPARATOR
Intervention: Experimental high potency preparation of 24 mg/ml
Number of subjects: 18
Study 30894240 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT skills group (DBT-SG)
Number of subjects: 17
Study 28431538 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscope (Group A)
Number of subjects: 300
Study 28431538 — intervention group
Group type: COMPARATOR
Intervention: Rigid ureteroscope (Group B)
Number of subjects: 300
Study 26154723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 39
Study 26154723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 39
Study 24522306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV)
Number of subjects: 50
Study 24522306 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time PCR for non polio EV
Number of subjects: 50
Study 24522306 — intervention group
Group type: COMPARATOR
Intervention: Control group with pre-vaccination blood sample (BS)
Number of subjects: 50
Study 22122960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta-carotene, vitamins C and E, and magnesium
Number of subjects: 0
Study 22122960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 0
Study 17700397 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone (up to 50 mg/day)
Number of subjects: 467
Study 17700397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study 15868595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK)
Number of subjects: 38
Study 15868595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15868595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 38
Study 11998815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 46
Study 11998815 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 46
Study 9673807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 2395
Study 9673807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2395
Study 9673807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 2395
Study 9673807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray (both dosages)
Number of subjects: 2395
Study 7633535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cost antibiotics (amoxicillin plus clavulanate potassium, cefaclor, or cefixime) for persistent middle ear effusions
Number of subjects: 66
Study 7633535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral decongestants (alone or in combination with other therapy) at the 6-week visit
Number of subjects: 66
Study 7633535 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for ventilating tube surgery at the 9-week visit
Number of subjects: 66
Study 7633535 — intervention group
Group type: COMPARATOR
Intervention: Management of recurrent episodes of acute otitis media
Number of subjects: 66
Study 2755214 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium alone (2 g potassium chloride daily)
Number of subjects: 10
Study 2755214 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium combined supplementation (2 g potassium and 1 g magnesium daily)
Number of subjects: 10
Study 329292 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (para-chlorphenyl-GABA)
Number of subjects: 21
Study 329292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31642588 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-flap approach
Number of subjects: 36
Study 31642588 — intervention group
Group type: COMPARATOR
Intervention: Flapless approach
Number of subjects: 36
Study 29231588 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy applied at bilateral Tianshu (ST 25), Changqiang (GV 1), bilateral Chengshan (BL 57) and Tigangxue (Extra), once a week for 4 weeks.
Number of subjects: 60
Study 29231588 — intervention group
Group type: COMPARATOR
Intervention: Western medication with 0.2% nitroglycerin ointment, applied externally on the wound, twice daily for 4 weeks.
Number of subjects: 60
Study 26334610 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed practice (12 repeated virtual mastoidectomies with practice blocks spaced in time)
Number of subjects: 43
Study 26334610 — intervention group
Group type: COMPARATOR
Intervention: Massed practice (12 repeated virtual mastoidectomies all in 1 day)
Number of subjects: 43
Study 26334610 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-integrated tutoring during the first 5 sessions
Number of subjects: 43
Study 26334610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontutored participants in the distributed practice group
Number of subjects: 43
Study 23715924 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (300 mg magnesium as citrate)
Number of subjects: 0
Study 23715924 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0
Study 23715924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21515290 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol monotherapy
Number of subjects: 46
Study 21515290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metoprolol and felodipin therapy
Number of subjects: 46
Study 21515290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 46
Study 18024955 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone gel
Number of subjects: 150
Study 18024955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jelly
Number of subjects: 150
Study 18024955 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 17059782 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 864
Study 17059782 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 864
Study 15120888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 2073
Study 12360593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (76.9 +/- 6.6 mg/day)
Number of subjects: 50
Study 12360593 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 50
Study 9706829 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors started within the first day after acute myocardial infarction and continued for 4 to 6 weeks.
Number of subjects: 0
Study 9706829 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors for patients with LVD.
Number of subjects: 0
Study 9706829 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors for patients without evidence of LVD.
Number of subjects: 0
Study 7654644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg 36 h before gemeprost)
Number of subjects: 62
Study 7654644 — intervention group
Group type: COMPARATOR
Intervention: Laminaria tent (medium-sized, inserted 12 h before gemeprost)
Number of subjects: 62
Study 7654644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 62
Study 7654644 — intervention group
Group type: COMPARATOR
Intervention: Laminaria tent
Number of subjects: 62
Study 2654350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (free alpha-tocopherol) administered parenterally and later orally at pharmacologic serum levels (5 mg/dl)
Number of subjects: 755
Study 2654350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755